iSign Solutions (ISGN) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 15, 2023
Document Information Line Items
Entity Registrant Name	iSign Solutions Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		6,332,736
Amendment Flag	false
Entity Central Index Key	0000727634
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-19301
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-2790442
Entity Address, Address Line One	2033 Gateway Place
Entity Address, Address Line Two	Suite 662
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95110
City Area Code	650
Local Phone Number	802-7888
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28	$ 68
Accounts receivable, net of allowance of $1 at March 31, 2023, and $0 at December 31, 2022.	90	108
Prepaid expenses and other current assets		19
Total current assets	118	195
Property and equipment, net	4	4
Other assets	3	4
Total assets	125	203
Current liabilities:
Accounts payable	374	371
Short-term debt – related party	1,599	1,547
Short-term debt other	1,725	1,725
Accrued compensation	163	69
Deferred compensation	219	219
Other accrued liabilities	1,954	1,850
Deferred revenue	64	185
Total current liabilities	6,098	5,966
Other long-term liabilities	795	758
Total liabilities	6,893	6,724
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.01 par value; 2,000,000 shares authorized; 6,333 shares issued and outstanding at March 31, 2023, and 6,333 at December 31, 2022, respectively	63	63
Treasury shares, 5 at March 31, 2023, and December 31, 2022, respectively	(325)	(325)
Additional paid in capital	130,145	130,141
Accumulated deficit	(136,651)	(136,400)
Total stockholders’ deficit	(6,768)	(6,521)
Total liabilities and stockholders’ deficit	$ 125	$ 203

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance (in Dollars)	$ 1	$ 0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	6,333	6,333
Common stock, shares outstanding	6,333	6,333
Treasury shares	5	5

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations Unaudited - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Product	$ 70	$ 80
Maintenance	157	175
Total revenue	227	255
Cost of sales:
Product	2	2
Maintenance	8	18
Research and development	167	161
Sales and marketing	85	54
General and administrative	128	160
Total operating costs and expenses	390	395
Loss from operations	(163)	(140)
Other income (expense) net	10
Interest expense:
Related party	(43)	(39)
Other	(55)	(52)
Loss before income tax expense	(251)	(231)
Income tax expense
Net loss	$ (251)	$ (231)
Basic net loss per common share (in Dollars per share)	$ (0.04)	$ (0.04)
Weighted average common shares outstanding, basic (in Shares)	6,333	6,332

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations Unaudited (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Diluted loss per common share	$ (0.11)	$ (0.08)
Weighted average common shares outstanding, diluted	6,332	6,048

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Deficit Unaudited - USD ($) shares in Thousands, $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulative Deficit	Total
Balance at Dec. 31, 2021	$ 63	$ (325)	$ 130,120	$ (135,689)	$ (5,831)
Balance (in Shares) at Dec. 31, 2021	6,322	5
Stock-based compensation			7		7
Cashless exercise of warrants
Cashless exercise of warrants (in Shares)	10
Net loss				(231)	(231)
Balance at Mar. 31, 2022	$ 63	$ (325)	130,127	(135,920)	(6,055)
Balance (in Shares) at Mar. 31, 2022	6,332	5
Balance at Dec. 31, 2022	$ 63	$ (325)	130,141	(136,400)	(6,521)
Balance (in Shares) at Dec. 31, 2022	6,333	5
Stock-based compensation			4		4
Cashless exercise of warrants
Net loss				(251)	(251)
Balance at Mar. 31, 2023	$ 63	$ (325)	$ 130,145	$ (136,651)	$ (6,768)
Balance (in Shares) at Mar. 31, 2023	6,333	5

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows Unaudited - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (251)	$ (231)
Adjustments to reconcile net loss to net cash provided by (Used in) operating activities:
Depreciation and amortization		1
Stock-based compensation	4	7
Changes in operating assets and liabilities:
Accounts receivable, net	18	30
Prepaid expenses and other assets	19	7
Gain on Settlement of account payable	10
Accounts payable	(7)	18
Accrued compensation	94	19
Other accrued and long-term liabilities	142	105
Deferred revenue	(121)	143
Net cash provided by operating activities	(92)	99
Cash flows from investing activities:
Acquisition of property and equipment		(3)
Net cash used in investing activities		(3)
Cash flows from financing activities:
Proceeds from of short-term debts related party
Proceeds from the issuance of short-term debt other		50
Payment of short-term debts related party	52	(30)
Payment of short-term debts other		(100)
Net cash provided by (used in) financing activities	52	(80)
Net increase in cash and cash equivalents	(40)	16
Cash and cash equivalents at beginning of period	68	40
Cash and cash equivalents at end of period	28	56
Supplementary disclosure of cash flow information
Interest paid		28
Income taxes paid
Accounts receivable advance converted to convertible note

Nature of Business, Basis of Pr

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies [Abstract]
Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies	1. Nature of Business and Summary of Significant Accounting Policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure, and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2023, the Company’s accumulated deficit was $136,651. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2023, the Company’s cash balance was $28. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements In August 2020, the FASB issued ASU2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06,the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, Earnings Per Share, for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Subtopic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2022, the Company early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s financial statements or disclosures. Reclassification of Prior Year Presentation The Company is reclassifying its consolidated financial statements for the year ended December 31, 2022 (the “2022 Consolidated Financial Statements”). The unaudited condensed financial statements represent a reclassification of certain prior year footnotes.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2023
Concentrations [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue 2023 2022 2023 2022 Customer #1 94 % 91 % 36 % 35 % Customer #2 - - 30 % 25 % Customer #3 - - 22 % 20 % Total concentration 94 % 91 % 88 % 80 % The following table summarizes sales concentrations: March 31, March 31, Sales within the United States 36 % 35 % Sales outside of the United States 64 % 65 % Total 100 % 100 %

Property and equipment

Property and equipment	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and equipment	3. Property and equipment: Property and equipment net consists of the following at: March 31, 2023 December 31, Computer equipment and software $ 32 $ 32 Less accumulated depreciation and amortization (28 ) (28 ) $ 4 $ 4

Other Accrued Liabilities

Other Accrued Liabilities	3 Months Ended
	Mar. 31, 2023
Other Accrued Liabilities [Abstract]
Other accrued liabilities	4. Other accrued liabilities The Company records other liabilities based on reasonable estimates for expenses, or payables that are known or estimated including deposits, taxes, rents, and services. The Company had the following other accrued liabilities at: March 31, December 31, Accrued interest $ 1,604 $ 1,507 Delaware Franchise tax 296 289 Other 54 54 Total $ 1,954 $ 1,850 The Company had the following other long-term accrued liabilities at: March 31, December 31, Management fees $ 795 $ 758 Total $ 795 $ 758

Debt

Debt	3 Months Ended
	Mar. 31, 2023
Debt [Abstract]
Debt	5. Debt: The table below break down the Company’s debt into its related components at: March 31, 2023 December 31, 2022 Advances Note Total Advances Note Total Short-term debt related party $ 232 $ 1,367 $ 1,599 $ 180 $ 1,367 $ 1,547 Short-term debt other $ - $ 1,725 $ 1,725 $ - $ 1,725 $ 1,725 Advances: In January 2022, the Company received, from unrelated parties, demand notes aggregating $50 in cash. The notes bear interest at the rate of 20% per annum. Principal and interest due shall be paid in full on demand, following ten (10) calendar day prior written notices starting on March 15, 2022. These notes may be prepaid in whole or in part at any time without penalty, premium or other consideration by giving at least five (5) business day prior written notice to the Holder. On January 19 and February 9, 2022, the Company repaid $15 and $15, respectively, of accounts receivable advances from related parties along with $2 of accrued advance fees. In addition, during February 2022, the Company repaid $100 of demand notes to an unrelated party along with 20% of accrued fees. In October 2022, the Company received, from related parties, advances aggregating $6 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company agreed to repay the advance to the lenders on a pro rata basis together with a 3% advance fee. In February and March 2023, the Company received, from related party, advances aggregating $52 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company agreed to repay the advance to the lenders on a pro rata basis together with a 2% advance fee. Notes payable: In January 2022, the Company received, from unrelated parties, demand notes aggregating $50 in cash. The notes bear interest at the rate of 20% per annum. Principal and interest due shall be paid in full on demand, following ten (10) calendar day prior written notices starting on March 15, 2022. These notes may be prepaid in whole or in part at any time without penalty, premium or other consideration by giving at least five (5) business day prior written notice to the Holder. The notes were repaid in full plus $1 of accrued interest in February 2022. In June 2022, the Company paid the second installment in the amount of $45 plus accrued interest of $4 of a note entered into associated with a settlement agreement dated July 1, 2020, with one of its vendors. The remaining $45 plus interest at the rate of 4% per annum is due in June of 2023. On April 20, 2022, the Company issued an aggregate of $125 in unsecured convertible notes, $70 to related parties and $55 to other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2022. On August 2022, the Company issued an aggregate of $50 in unsecured convertible notes to other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2022. On November 2022, the Company issued an aggregate of $75 in unsecured convertible notes, $35 to related parties and $40 to other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2022. On December 2022, the Company issued an aggregate of $72 in unsecured convertible notes, $25 to related parties and $47 to other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2022. During the three months ended March 31, 2023, the Company accrued a total of $98 in interest expense, $75 on notes only, of which $34 was to the related parties and $41 was to other investors in the three months ended 2023. During the three months ended March 31, 2022, the Company accrued a total of $91 in interest expense, $67 on notes only, of which $30 was to the related parties and $37 was to other investors in the three months ended 2022.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2023
Stockholders’ Deficit [Abstract]
Stockholders' Deficit	6. Stockholders’ Deficit: Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2023, and 2022 was approximately 4.78% and 4.78%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. No no The following table summarizes the allocation of stock-based compensation expense for the three months ended March 31: 2023 2022 General and administrative $ 3 $ 5 Director 1 2 Total stock-based compensation $ 4 $ 7 A summary of option activity under the Company’s plans for the three months ended March 31, 2023, and 2022 is as follows: 2023 2022 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1 1,297 $ 0.59 - $ - 1,338 $ 0.84 - 800 Granted - $ - - $ - - - Canceled - $ - - - 16 $ 28.12 24.57 Outstanding at March 31 1,297 $ 0.59 0.59 $ - 1,322 $ 0.60 0.50 1,100 Vested and expected to vest at March 31 1,297 $ 0.59 1.36 $ - 1,322 $ 0.84 3.17 $ 1,100 Exercisable at March 31 1,250 $ 0.59 2.30 $ - 1,182 $ 0.61 3.14 $ 967 The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2023: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.01 - $0.50 910 0.50 $ 2.39 863 $ 0.50 $0.51 - $1.00 386 0.78 $ 2.36 386 $ 0.78 $1.01 - $25.00 1 10.00 $ 0.00 1 $ 10.00 Total 1,297 0.59 $ 2.38 1,250 $ 0.59 A summary of the status of the Company’s non-vested shares as of March 31, 2023, is as follows: Non-vested Shares Shares Weighted Non-vested at January 1, 2022 70 $ 0.50 Vested (23 ) $ 0.50 Non-vested at March 31, 2023 47 $ 0.50 As of March 31, 2023, there was $4 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of one year. Warrants The Company did not issue any warrants during the three months ended March 31, 2023, and 2022. A summary of the warrant activity to purchase shares of Common Stock for the three months ended March 31 is as follows: 2023 2022 Shares Weighted Shares Weighted Outstanding at beginning of period 450 $ 1.52 1,450 $ 1.52 Issued - $ - - $ - Exercised - $ - (15 ) $ 0.50 Expired (15 ) $ 0.50 (985 ) $ 0.50 Outstanding at end of period 435 $ 0.50 450 $ 0.50 Exercisable at end of period 435 $ 0.50 450 $ 0.50 A summary of the status of the warrants outstanding and exercisable to purchase shares of Common Stock as of March 31, 2023, is as follows: Number of Shares Weighted Average Remaining Life Weighted Average Exercise Price per share 15 0.84 $ 0.50 10 3.32 $ 0.50 425 1.38 $ 0.50 450 1.41 $ 0.50

Related party

Related party	3 Months Ended
	Mar. 31, 2023
Related party [Abstract]
Related party	7. Related party Phoenix is the beneficial owner of approximately 16.9% of the Common Stock of the Company when calculated in accordance with Rule 13d-3. On April 20, 2022, the Company issued an aggregate of $70 in unsecured convertible notes to related parties. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2022. On November 2022, the Company issued an aggregate of $35 in unsecured convertible notes to related parties. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2023. On December 2022, the Company issued an aggregate of $35 in unsecured convertible notes to related parties. and $37 to other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2023. There were no stock option grants to affiliates of the Company during the three months ended March 31, 2023, and 2022.

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitment and Contingencies [Abstract]
Commitments and Contingencies	8. Commitment and Contingencies Lease commitments The Company maintains no leases. The Company rents approximately 120 square feet of office space in San Jose California. The office space is on a month-to-month rental basis and can be surrendered at any time without penalty. Office rent expenses were approximately $7 and $10 in the three months ended March 2023 and 2022, respectively. Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Net Loss Per Share_

Net Loss Per Share:	3 Months Ended
	Mar. 31, 2023
Net Loss Per Share [Abstract]
Net Loss Per Share:	9. Net Loss Per Share: The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the inclusion of shares from the assumed exercise of such options and warrants would be anti-dilutive: For the Three Months Ended March 31, March 31, Common stock subject to outstanding options 1,297 1,322 Common stock subject to outstanding warrants 435 450 Common stock subject to outstanding convertible debt plus accrued interest 8,766 7,556

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Event [Abstract]
Subsequent events	10. Subsequent event: In April 2023, the Company repaid advances aggregating $59 of accounts receivable advances from related parties along with $1 of accrued advance fees. Forward Looking Statements Certain statements contained in this quarterly report on Form 10-Q, including, without limitation, statements containing the words “believes”, “anticipates”, “hopes”, “intends”, “expects”, and other words of similar import, constitute “forward looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual events to differ materially from expectations. Such factors include those set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, including the following: ● Technological, engineering, manufacturing, quality control or other circumstances that could delay the sale or shipment of products; ● Economic, business, market and competitive conditions in the software industry and technological innovations that could affect the Company’s business; ● The Company’s inability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the proprietary rights of the Company; and ● General economic and business conditions and the availability of sufficient financing. Except as otherwise required by applicable laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, as a result of new information, future events or otherwise.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure, and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs.
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2023, the Company’s accumulated deficit was $136,651. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2023, the Company’s cash balance was $28. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements In August 2020, the FASB issued ASU2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06,the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. Similarly, equity-classified convertible preferred stock instruments will be accounted for as single units of account in equity unless the conversion feature needs to be bifurcated under Topic 815. The new guidance also made amendments to the earnings per share guidance in Topic 260, Earnings Per Share, for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted earnings per share calculation. Further, ASU 2020-06 made revisions to Subtopic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. Effective January 1, 2022, the Company early adopted ASU 2020-06 using the modified retrospective approach. Adoption of the new standard did not have a material impact on the Company’s financial statements or disclosures.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation The Company is reclassifying its consolidated financial statements for the year ended December 31, 2022 (the “2022 Consolidated Financial Statements”). The unaudited condensed financial statements represent a reclassification of certain prior year footnotes.

Concentrations (Tables)

Concentrations (Tables)	3 Months Ended
	Mar. 31, 2023
Concentrations [Abstract]
Schedule of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue 2023 2022 2023 2022 Customer #1 94 % 91 % 36 % 35 % Customer #2 - - 30 % 25 % Customer #3 - - 22 % 20 % Total concentration 94 % 91 % 88 % 80 %
Schedule of sales concentrations	March 31, March 31, Sales within the United States 36 % 35 % Sales outside of the United States 64 % 65 % Total 100 % 100 %

Property and equipment (Tables)

Property and equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	March 31, 2023 December 31, Computer equipment and software $ 32 $ 32 Less accumulated depreciation and amortization (28 ) (28 ) $ 4 $ 4

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Other Accrued Liabilities [Abstract]
Schedule of other accrued liabilities	March 31, December 31, Accrued interest $ 1,604 $ 1,507 Delaware Franchise tax 296 289 Other 54 54 Total $ 1,954 $ 1,850
Schedule of other long-term accrued liabilities	March 31, December 31, Management fees $ 795 $ 758 Total $ 795 $ 758

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt [Abstract]
Schedule of debt into its related components	March 31, 2023 December 31, 2022 Advances Note Total Advances Note Total Short-term debt related party $ 232 $ 1,367 $ 1,599 $ 180 $ 1,367 $ 1,547 Short-term debt other $ - $ 1,725 $ 1,725 $ - $ 1,725 $ 1,725

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2023
Stockholders’ Deficit [Abstract]
Schedule of allocation of stock-based compensation expense	2023 2022 General and administrative $ 3 $ 5 Director 1 2 Total stock-based compensation $ 4 $ 7
Schedule of warrants outstanding and exercisable	2023 2022 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1 1,297 $ 0.59 - $ - 1,338 $ 0.84 - 800 Granted - $ - - $ - - - Canceled - $ - - - 16 $ 28.12 24.57 Outstanding at March 31 1,297 $ 0.59 0.59 $ - 1,322 $ 0.60 0.50 1,100 Vested and expected to vest at March 31 1,297 $ 0.59 1.36 $ - 1,322 $ 0.84 3.17 $ 1,100 Exercisable at March 31 1,250 $ 0.59 2.30 $ - 1,182 $ 0.61 3.14 $ 967
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Term (in years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $0.01 - $0.50 910 0.50 $ 2.39 863 $ 0.50 $0.51 - $1.00 386 0.78 $ 2.36 386 $ 0.78 $1.01 - $25.00 1 10.00 $ 0.00 1 $ 10.00 Total 1,297 0.59 $ 2.38 1,250 $ 0.59
Schedule of the company's non-vested shares	Non-vested Shares Shares Weighted Non-vested at January 1, 2022 70 $ 0.50 Vested (23 ) $ 0.50 Non-vested at March 31, 2023 47 $ 0.50
Schedule of warrant activity	2023 2022 Shares Weighted Shares Weighted Outstanding at beginning of period 450 $ 1.52 1,450 $ 1.52 Issued - $ - - $ - Exercised - $ - (15 ) $ 0.50 Expired (15 ) $ 0.50 (985 ) $ 0.50 Outstanding at end of period 435 $ 0.50 450 $ 0.50 Exercisable at end of period 435 $ 0.50 450 $ 0.50
Schedule of warrants outstanding and exercisable	Number of Shares Weighted Average Remaining Life Weighted Average Exercise Price per share 15 0.84 $ 0.50 10 3.32 $ 0.50 425 1.38 $ 0.50 450 1.41 $ 0.50

Net Loss Per Share_ (Tables)

Net Loss Per Share: (Tables)	3 Months Ended
	Mar. 31, 2023
Net Loss Per Share [Abstract]
Schedule of shares and warrants that were excluded from the calculation of diluted earnings per share	For the Three Months Ended March 31, March 31, Common stock subject to outstanding options 1,297 1,322 Common stock subject to outstanding warrants 435 450 Common stock subject to outstanding convertible debt plus accrued interest 8,766 7,556

Nature of Business, Basis of _2

Nature of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Accumulated deficit	$ 136,651
Cash	$ 28

Concentrations (Details) - Sche

Concentrations (Details) - Schedule of accounts receivable and revenue concentrations - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable [Member]
Variable Interest Entity [Line Items]
Total concentration	94%	91%
Accounts Receivable [Member] | Customer #1 [Member]
Variable Interest Entity [Line Items]
Total concentration	94%	91%
Accounts Receivable [Member] | Customer #2 [Member]
Variable Interest Entity [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #4 [Member]
Variable Interest Entity [Line Items]
Total concentration
Total Revenue [Member]
Variable Interest Entity [Line Items]
Total concentration	88%	80%
Total Revenue [Member] | Customer #1 [Member]
Variable Interest Entity [Line Items]
Total concentration	36%	35%
Total Revenue [Member] | Customer #2 [Member]
Variable Interest Entity [Line Items]
Total concentration	30%	25%
Total Revenue [Member] | Customer #4 [Member]
Variable Interest Entity [Line Items]
Total concentration	22%	20%

Concentrations (Details) - Sc_2

Concentrations (Details) - Schedule of sales concentrations	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Concentrations (Details) - Schedule of sales concentrations [Line Items]
Concentration risk, percentage of total sales	100%	100%
Sales within the United States [Member]
Concentrations (Details) - Schedule of sales concentrations [Line Items]
Concentration risk, percentage of total sales	36%	35%
Sales outside of the United States [Member]
Concentrations (Details) - Schedule of sales concentrations [Line Items]
Concentration risk, percentage of total sales	64%	65%

Property and equipment (Details

Property and equipment (Details) - Schedule of property and equipment, net - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule of Property And Equipment Net [Abstract]
Computer equipment and software	$ 32	$ 32
Less accumulated depreciation and amortization	(28)	(28)
Property and equipment, net	$ 4	$ 4

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - Schedule of other accrued liabilities - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule of Other Accrued Liabilities [Abstract]
Accrued interest	$ 1,604	$ 1,507
Delaware Franchise tax	296	289
Other	54	54
Total	$ 1,954	$ 1,850

Other Accrued Liabilities (De_2

Other Accrued Liabilities (Details) - Schedule of other long-term accrued liabilities - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule of Other Long-Term Accrued Liabilities [Abstract]
Management fees	$ 795	$ 758
Total	$ 795	$ 758

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended										3 Months Ended
	Feb. 09, 2022	Jan. 19, 2022	Mar. 31, 2023	Feb. 28, 2023	Dec. 31, 2022	Nov. 30, 2022	Oct. 31, 2022	Aug. 31, 2022	Jun. 30, 2022	Apr. 20, 2022	Feb. 28, 2022	Jan. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Debt (Details) [Line Items]
Accounts receivable advances in cash							$ 6					$ 50
Percentage of bear interest rate												20%
Advance accounts receivable	$ 15	$ 15
Accrued advances fees													$ 2
Accounts receivable advances repaid											$ 100
Accrued fees percentage											20%
Advance fee percentage			2%	2%			3%
Cash received			$ 52	$ 52
Accrued interest expense											$ 1
Paid installment amount									$ 45
Related parties					$ 25	$ 35			4	$ 70
Interest expense									$ 45				98	$ 91
Interest at the rate					10%	10%		10%	4%
Unsecured amount					$ 72	$ 75		$ 50		125
Due to other investors					47	40				55
Aggregate proceeds					$ 1,000	$ 1,000		$ 1,000		$ 1,000
Notes associated													75	67
Related parties notes			34										34	30
Other investors			$ 41										$ 41	$ 37
Notes payable [Member]
Debt (Details) [Line Items]
Percentage of bear interest rate												20%
Cash received from related party												$ 50
Interest at the rate					10%
Price per share (in Dollars per share)					$ 1	$ 1		$ 1		$ 1
Common Stock [Member]
Debt (Details) [Line Items]
Price per share (in Dollars per share)					$ 1	$ 1		$ 1		$ 1

Debt (Details) - Schedule of de

Debt (Details) - Schedule of debt into its related components - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt (Details) - Schedule of debt into its related components [Line Items]
Short-term debt related party	$ 1,599	$ 1,547
Short-term debt other	1,725	1,725
Advances [Member]
Debt (Details) - Schedule of debt into its related components [Line Items]
Short-term debt related party	232	180
Short-term debt other
Note Payable [Member]
Debt (Details) - Schedule of debt into its related components [Line Items]
Short-term debt related party	1,367	1,367
Short-term debt other	$ 1,725	$ 1,725

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stockholders’ Deficit [Abstract]
Estimated average forfeiture rate	4.78%	4.78%
Total unrecognized compensation expense	$ 4
Weighted average period	1 year
Stock options granted (in Shares)
Stock options exercised

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Schedule of allocation of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stockholders' Deficit (Details) - Schedule of allocation of stock-based compensation expense [Line Items]
Total stock-based compensation expense	$ 4	$ 7
Director options and consultants [Member]
Stockholders' Deficit (Details) - Schedule of allocation of stock-based compensation expense [Line Items]
Total stock-based compensation expense	1	2
General and administrative [Member]
Stockholders' Deficit (Details) - Schedule of allocation of stock-based compensation expense [Line Items]
Total stock-based compensation expense	$ 3	$ 5

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable - Option [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Shares, Outstanding at beginning	1,297,000
Weighted Average Exercise Price per share, Outstanding at beginning	$ 0.59
Weighted Average Remaining Contractual Life (in years), Outstanding at beginning
Aggregate Intrinsic Value, Outstanding at beginning
Shares, Granted
Weighted Average Remaining Contractual Life (in years), Granted
Shares, Canceled
Weighted Average Exercise Price per share, Canceled
Weighted Average Remaining Contractual Life (in years), Canceled
Aggregate Intrinsic Value, Canceled
Shares, Outstanding at ending	1,297,000
Weighted Average Exercise Price per share, Outstanding at ending	$ 0.59
Weighted Average Remaining Contractual Life (in years), Outstanding at ending	7 months 2 days
Aggregate Intrinsic Value, Outstanding at ending
Shares, Vested and expected to vest	1,297,000
Weighted Average Exercise Price per share, Vested and expected to vest	$ 0.59
Weighted Average Remaining Contractual Life (in years), Vested and expected to vest	1 year 4 months 9 days
Aggregate Intrinsic Value, Vested and expected to vest
Shares, Exercisable	1,250,000
Weighted Average Exercise Price per share, Exercisable	$ 0.59
Weighted Average Remaining Contractual Life (in years), Exercisable	2 years 3 months 18 days
Aggregate Intrinsic Value, Exercisable
Previously Reported [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Shares, Outstanding at beginning		1,338,000
Weighted Average Exercise Price per share, Outstanding at beginning		$ 0.84
Weighted Average Remaining Contractual Life (in years), Outstanding at beginning
Aggregate Intrinsic Value, Outstanding at beginning		$ 800
Shares, Granted
Weighted Average Exercise Price per share, Granted
Weighted Average Remaining Contractual Life (in years), Granted
Aggregate Intrinsic Value, Granted
Shares, Canceled		16,000
Weighted Average Exercise Price per share, Canceled		$ 28.12
Weighted Average Remaining Contractual Life (in years), Canceled		24 years 6 months 25 days
Shares, Outstanding at ending		1,322,000
Weighted Average Exercise Price per share, Outstanding at ending		$ 0.6
Weighted Average Remaining Contractual Life (in years), Outstanding at ending		6 months
Aggregate Intrinsic Value, Outstanding at ending		$ 1,100
Shares, Vested and expected to vest		1,322,000
Weighted Average Exercise Price per share, Vested and expected to vest		$ 0.84
Weighted Average Remaining Contractual Life (in years), Vested and expected to vest		3 years 2 months 1 day
Aggregate Intrinsic Value, Vested and expected to vest		$ 1,100
Shares, Exercisable		1,182,000
Weighted Average Exercise Price per share, Exercisable		$ 0.61
Weighted Average Remaining Contractual Life (in years), Exercisable		3 years 1 month 20 days
Aggregate Intrinsic Value, Exercisable		$ 967

Stockholders' Deficit (Detail_4

Stockholders' Deficit (Details) - Schedule of significant ranges of outstanding and exercisable options shares in Thousands	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,297
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 months 2 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 2.38
Options Exercisable, Number Outstanding | shares	1,250
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.59
$0.01 – $0.50 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	910
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 months
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 2.39
Options Exercisable, Number Outstanding | shares	863
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.5
$0.51 – $1.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	386
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	9 months 10 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 2.36
Options Exercisable, Number Outstanding | shares	386
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.78
$1.01 – $625.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	10 years
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 0
Options Exercisable, Number Outstanding | shares	1
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 10

Stockholders' Deficit (Detail_5

Stockholders' Deficit (Details) - Schedule of the company's non-vested shares shares in Thousands	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Schedule of the companys non vested shares [Abstract]
Shares, Non-vested at beginning | shares	70
Weighted Average Grant-Date Fair Value, Shares | $ / shares	$ 0.5
Shares, Non-vested at ending | shares	47
Weighted Average Grant-Date Fair Value, Non-vested at ending | $ / shares	$ 0.5
Shares, Vested | shares	(23)
Weighted Average Grant-Date Fair Value, Vested | $ / shares	$ 0.5

Stockholders' Deficit (Detail_6

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member] - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]
Shares Outstanding at beginning of period	450
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 1.52
Shares, Exercisable at end of period	435
Weighted Average Exercise Price Per Share, Exercisable at end of period	$ 0.5
Shares, Issued
Weighted Average Exercise Price Per Share, Issued
Shares, Exercised
Weighted Average Exercise Price Per Share, Exercised
Shares, Expired	(15)
Weighted Average Exercise Price Per Share, Expired	$ 0.5
Shares, Outstanding at end of period	435
Weighted Average Exercise Price Per Share, Outstanding at end of period	$ 0.5
Previously Reported [Member]
Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]
Shares Outstanding at beginning of period		1,450
Weighted Average Exercise Price Per Share, Outstanding at beginning of period		$ 1.52
Shares, Exercisable at end of period		450
Weighted Average Exercise Price Per Share, Exercisable at end of period		$ 0.5
Shares, Issued
Weighted Average Exercise Price Per Share, Issued
Shares, Exercised		(15)
Weighted Average Exercise Price Per Share, Exercised		$ 0.5
Shares, Expired		(985)
Weighted Average Exercise Price Per Share, Expired		$ 0.5
Shares, Outstanding at end of period		450
Weighted Average Exercise Price Per Share, Outstanding at end of period		$ 0.5

Stockholders' Deficit (Detail_7

Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable shares in Thousands	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	450
Weighted Average Remaining Life (in years)	1 year 4 months 28 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5
Warrants Group One [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	15
Weighted Average Remaining Life (in years)	10 months 2 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5
Warrants Group Two [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	10
Weighted Average Remaining Life (in years)	3 years 3 months 25 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5
Warrants Group Three [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	425
Weighted Average Remaining Life (in years)	1 year 4 months 17 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5

Related party (Details)

Related party (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended
	Dec. 31, 2022	Nov. 30, 2022	Apr. 20, 2022	Mar. 31, 2023
Related party (Details) [Line Items]
Beneficial owner percentage				16.90%
Aggregate proceeds	$ 1,000	$ 1,000	$ 1,000
Conversion price (in Dollars per share)	$ 1	$ 1	$ 1
Common Stock [Member]
Related party (Details) [Line Items]
Unsecured notes price per share (in Dollars per share)	$ 1		$ 1
Price per share (in Dollars per share)		$ 1
Related Party [Member]
Related party (Details) [Line Items]
Unsecured convertible notes	$ 35	$ 35	$ 70
Interest rate	10%	10%	10%
Other investors	$ 37

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) m²	Mar. 31, 2022 USD ($)
Commitment and Contingencies [Abstract]
Office space (in Square Meters) | m²	120
Office rent expense | $	$ 7	$ 10

Net Loss Per Share_ (Details) -

Net Loss Per Share: (Details) - Schedule of shares and warrants that were excluded from the calculation of diluted earnings per share - shares	Mar. 31, 2023	Mar. 31, 2022
Schedule of shares and warrants that were excluded from the calculation of diluted earnings per share [Abstract]
Common stock subject to outstanding options	1,297,000	1,322,000
Common stock subject to outstanding warrants	435,000	450,000
Common stock subject to outstanding convertible debt plus accrued interest	8,766,000	7,556,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] $ in Thousands	Apr. 30, 2023 USD ($)
Subsequent Events (Details) [Line Items]
Accounts receivable advances	$ 59
Accrued advance fees	$ 1